Smith Asset Management Group LP decreased its position in United Therapeutics Corp. (NASDAQ:UTHR) by 0.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 279,156 shares of the biotechnology company’s stock after selling 1,034 shares during the period. Smith Asset Management Group LP’s holdings in United Therapeutics Corp. were worth $29,568,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the company. Scopia Capital Management LP boosted its stake in shares of United Therapeutics Corp. by 48.1% in the first quarter. Scopia Capital Management LP now owns 4,219,281 shares of the biotechnology company’s stock worth $470,154,000 after buying an additional 1,370,698 shares in the last quarter. BlackRock Fund Advisors boosted its stake in shares of United Therapeutics Corp. by 1.7% in the first quarter. BlackRock Fund Advisors now owns 2,158,943 shares of the biotechnology company’s stock worth $240,571,000 after buying an additional 35,288 shares in the last quarter. State Street Corp boosted its stake in shares of United Therapeutics Corp. by 6.1% in the first quarter. State Street Corp now owns 1,846,710 shares of the biotechnology company’s stock worth $205,778,000 after buying an additional 105,824 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of United Therapeutics Corp. by 7.1% in the second quarter. Acadian Asset Management LLC now owns 1,172,270 shares of the biotechnology company’s stock worth $124,167,000 after buying an additional 77,552 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of United Therapeutics Corp. by 21.1% in the first quarter. Geode Capital Management LLC now owns 455,719 shares of the biotechnology company’s stock worth $50,761,000 after buying an additional 79,502 shares during the period.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded up 0.55% on Tuesday, reaching $123.44. 593,412 shares of the company were exchanged. The stock has a market capitalization of $5.37 billion, a PE ratio of 5.97 and a beta of 1.46. United Therapeutics Corp. has a 1-year low of $97.52 and a 1-year high of $164.04. The company has a 50-day moving average price of $124.24 and a 200 day moving average price of $116.01.

United Therapeutics Corp. (NASDAQ:UTHR) last announced its quarterly earnings data on Thursday, July 28th. The biotechnology company reported $4.55 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.22 by $1.33. The business had revenue of $412.60 million for the quarter, compared to analyst estimates of $395.15 million. United Therapeutics Corp. had a net margin of 64.26% and a return on equity of 49.30%. The company’s revenue was up 18.8% on a year-over-year basis. During the same period in the prior year, the firm posted $2.55 EPS. On average, analysts forecast that United Therapeutics Corp. will post $15.82 EPS for the current fiscal year.

UTHR has been the subject of a number of research reports. Wedbush restated an “outperform” rating and issued a $229.00 price objective on shares of United Therapeutics Corp. in a report on Thursday, July 28th. HC Wainwright restated a “hold” rating on shares of United Therapeutics Corp. in a report on Friday, July 29th. Zacks Investment Research upgraded shares of United Therapeutics Corp. from a “hold” rating to a “strong-buy” rating and set a $125.00 price objective for the company in a report on Tuesday, July 5th. Argus cut shares of United Therapeutics Corp. from a “buy” rating to a “hold” rating and set a $114.00 price objective for the company. in a report on Tuesday, May 24th. Finally, Jefferies Group restated a “hold” rating and issued a $120.00 price objective on shares of United Therapeutics Corp. in a report on Friday, July 29th. Nine research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $135.64.

In other news, CEO Martine A. Rothblatt sold 1,308 shares of the stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $105.10, for a total transaction of $137,470.80. Following the transaction, the chief executive officer now directly owns 1,548 shares in the company, valued at approximately $162,694.80. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 1,249 shares of the stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $125.78, for a total transaction of $157,099.22. Following the transaction, the chief executive officer now owns 1,389 shares in the company, valued at $174,708.42. The disclosure for this sale can be found here. Insiders own 7.50% of the company’s stock.

About United Therapeutics Corp.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corp. (NASDAQ:UTHR).

Receive News & Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.